A senior leader mid-conversation with colleagues in a bright open-plan office
Journal Executive health 8 min read
Measuring early

The best time to measure is while you still feel fine.

A preventive health assessment does its best work before anything feels wrong. The things that cost you most later build quietly for years, and while you are well they are at their easiest to change.

Quick Answer

A preventive health assessment is worth doing while you still feel fine, because the changes that cost you most later build quietly for years first. Blood sugar control, blood pressure and artery health can all drift for years before anything feels different, and in that early window small changes still work.

Measuring while you are well also gives you a baseline: your own numbers in a good year. Every later result can be read against it, so a shift that matters for you shows up early, even when it still sits inside the printed range.

At a glance
01

In a study of 6,538 office workers, insulin sensitivity was already falling steeply five years before diabetes was diagnosed. Fasting blood sugar only climbed sharply in the last three.

02

Among 4,184 adults aged 40 to 54 with no symptoms, 63% already had plaque in at least one artery.

03

Worldwide, about half of men with high blood pressure had never been told they had it.

04

Caught at the warning stage, blood sugar responds to everyday changes. In a large trial, lifestyle change cut new cases of diabetes by 58% over about three years.

05

Your own results usually sit in a narrow band inside the lab’s printed range, so a baseline lets you see a change before anything is flagged.

Feeling fine

You can feel well for years while things drift.

Most of what slows a senior leader down in their fifties and sixties starts in their forties, and it starts without a sound. Raised blood pressure has no feeling. Neither does plaque forming in an artery wall, or a body that needs a little more insulin each year to handle the same lunch.

When researchers in Spain scanned the arteries of 4,184 working adults aged 40 to 54, none of whom had symptoms, 63% already had plaque somewhere in their body. Among the people whose standard risk score called them low risk, 58% still did.1

Blood pressure tells the same story. A pooled analysis of 104 million people found that in 2019 roughly half of men and four in ten women with high blood pressure had never been diagnosed.2 Those figures are worldwide, but the reason behind them is universal: you cannot feel it.

This isn’t cause for alarm. Each of these shows up on a test well before it shows up in how you feel, and that is what makes looking worthwhile.

The quiet years

Your body gives you years of warning.

The clearest picture of how long the warning lasts comes from Whitehall II, a long-running study of 6,538 British civil servants, an office workforce followed for about ten years. Among those who went on to develop type 2 diabetes, insulin sensitivity fell steeply across the five years before diagnosis. Fasting blood sugar barely moved until the last three years, then rose quickly.3

So the number most people know about is the one that moves last. The body spends years working harder behind the scenes to keep blood sugar looking normal, and that extra effort can be measured long before the sugar itself gives way.

Those years are the useful ones. Nothing has broken yet, and the body still responds to modest changes in how you eat, move and sleep.

If you only measure at the end, you only ever find the end of the story.
The cost of waiting

Finding out late is the expensive way to find out.

Early matters because early is when the simple fixes still work. The Diabetes Prevention Program enrolled 3,234 adults whose blood sugar was already drifting upward but had not yet crossed into diabetes. The lifestyle group aimed for at least 150 minutes of activity a week and a modest weight loss. Over about three years, that cut the rate of new diabetes by 58%.4

That is what measuring early buys you. Once a problem is established, the fixes get bigger and take more of your time and attention away from the work you would rather be doing.

The cost I’d put in front of anyone whose job is judgement is less obvious. In the ARIC study, which followed more than 13,000 adults, high blood pressure in midlife (between 48 and 67) was linked to more decline in memory and thinking over the following 20 years. Blood pressure measured late in life was not linked to that earlier decline.5 The window that seems to matter most is midlife: the stretch when most people feel too well to check, and want another decade or two of performing at their best.

Your baseline

A baseline is what every later result is read against.

A lab’s printed range is built from thousands of people, so it is wide by design. Your own results, measured a few times while you are steady, usually sit in a much narrower band inside it. In a study of 784 adults across 27 common blood tests, each person’s own range took up only a small part of the population range, and three earlier results were enough to set it reliably.6

The consequence is simple. A result can move a long way for you and still sit comfortably inside the printed range. Without your earlier numbers, nobody can see that it moved.

Following people against their own history turns that into findings. Researchers at Stanford tested 109 adults every three months for up to eight years and made more than 67 clinically useful findings they could act on. Most participants went on to change how they ate or exercised.7 A separate study of 108 adults concluded that measuring the same people over time can help spot early transitions toward disease, and that coaching built on each person’s own data improved their clinical markers.8

The best baseline is the one taken in a good year. Take your first one after you start to feel unwell and the only picture you have to compare against is unwell.

What drifts quietly

Markers worth having on file early.

These are measures that can shift for years without a symptom. Each is more useful read against your own earlier result than read on its own.

Marker What it shows Why an early baseline helps
Fasting insulinHow hard the body works to hold blood sugar steadyIt can rise years before fasting glucose does
HbA1cAverage blood sugar over about three monthsA slow upward creep is easy to miss without an earlier result
ApoBThe number of particles that can lodge in artery wallsArtery risk builds silently, years ahead of symptoms
hs-CRPLow-grade background inflammationYour usual level gives a single high reading context
ALT and GGTStrain on the liverThey can drift up while staying inside the printed range
FerritinIron storesShapes energy and exercise capacity in both directions
Being honest

What measuring early can and can’t do.

Measuring early is not a guarantee. Several of the studies above show links rather than proof of cause, and a pattern found in one population will not map exactly onto your own biology. A single assessment also tells you less than people hope: it is a starting point, and its value grows with each repeat.

What the evidence does support is narrower and more useful. The things that matter most build quietly and are easier to change early, and you can only see a change if you know where you started. For a fuller picture of what a well-year assessment should include, see what an executive health check should measure, and for the artery side in particular, the risk you can’t feel. If you have noticed that you bounce back more slowly than you used to, why recovery takes longer covers the pace-of-ageing side of the same question.

Measured while well.
Read against yourself.
Repeated over years 
→

One result is a snapshot. Your own trend is the story.

Key takeaways

What the evidence supports.

Insulin sensitivity can fall steeply for five years before type 2 diabetes is diagnosed, while fasting blood sugar rises sharply only in the final three.

Most middle-aged adults with no symptoms already carry some arterial plaque; in one study of 40 to 54 year olds it was 63%.

Lifestyle change at the pre-diabetes stage cut new cases of diabetes by 58% over about three years in a large randomised trial.

High blood pressure in midlife, not late life, was linked to greater decline in memory and thinking over 20 years.

A personal range built from about three earlier results is far narrower than the population range, so a baseline makes change visible early.

Frequently asked.

Is a preventive health assessment worth it if I feel healthy?

Yes, and feeling healthy is the best time to do one. Blood sugar control, blood pressure and artery health can all drift for years without symptoms, and changes caught early respond to simpler measures. A test taken while you are well also becomes the baseline every later result is read against.

Why does a baseline matter if my results are normal?

A lab range covers thousands of people, so it is wide. Your own results usually sit in a much narrower band inside it. A result can move a long way for you and still look normal on the page, and only an earlier result shows that it moved.

What is one of the earliest blood test signs of diabetes risk?

In a large study of office workers, insulin sensitivity was falling steeply about five years before diabetes was diagnosed, well before fasting blood sugar rose sharply. Fasting insulin and related measures can show that extra effort years before glucose changes.

How many results do I need before my baseline is reliable?

Research on personal reference ranges found that three earlier results, taken while a person was steady, were enough to set a reliable personal range for common blood tests. One result is a starting point, and each repeat makes the picture clearer.

What should a preventive health assessment include?

At a minimum it should cover metabolic health, artery risk, liver, thyroid, iron and inflammation, ideally alongside stress-hormone rhythm and recovery. Just as important, it should be repeated, so each result can be compared with your own earlier numbers.

Performance Biology · Functional Medicine

Measure while you’re well.

A structured protocol built on comprehensive testing, then measured year on year against your own baseline. Telehealth, Australia-wide.

Book a discovery call The way back to full capacity

References.

  1. Fernández-Friera L, Peñalvo JL, Fernández-Ortiz A, et al. Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort: the PESA (Progression of Early Subclinical Atherosclerosis) study. Circulation. 2015;131(24):2104–13. doi.org/10.1161/CIRCULATIONAHA.114.014310
  2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–980. doi.org/10.1016/S0140-6736(21)01330-1
  3. Tabák AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimäki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215–21. doi.org/10.1016/S0140-6736(09)60619-X
  4. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. doi.org/10.1056/NEJMoa012512
  5. Gottesman RF, Schneider AL, Albert M, et al. Midlife hypertension and 20-year cognitive change: the Atherosclerosis Risk in Communities Neurocognitive Study. JAMA Neurol. 2014;71(10):1218–27. doi.org/10.1001/jamaneurol.2014.1646
  6. Coşkun A, Sandberg S, Unsal I, et al. Personalized reference intervals in laboratory medicine: a new model based on within-subject biological variation. Clin Chem. 2021;67(2):374–384. doi.org/10.1093/clinchem/hvaa233
  7. Schüssler-Fiorenza Rose SM, Contrepois K, Moneghetti KJ, et al. A longitudinal big data approach for precision health. Nat Med. 2019;25(5):792–804. doi.org/10.1038/s41591-019-0414-6
  8. Price ND, Magis AT, Earls JC, et al. A wellness study of 108 individuals using personal, dense, dynamic data clouds. Nat Biotechnol. 2017;35(8):747–756. doi.org/10.1038/nbt.3870

This article is general information. It is not a substitute for individual medical advice.

Similar Posts